Why Are My Lymph Nodes Swollen If It Is Not Lymphoma? Castleman Disease

Medically reviewed by Dr. Michael Kachur · Frankfurt, Germany·

The scan found enlarged lymph nodes. Someone said the word lymphoma out loud, a node came out, and the result was not lymphoma. It was Castleman disease, a name nobody in the room had used before. That is a strange kind of relief, because the next question has no obvious answer: if it is not a lymphoma, what is it, and is it serious? That depends on one thing, and the first scan does not settle it. It takes the biopsy, the blood work and the imaging read as one connected record, which is what Healz's root-cause technology is built to do with a label that has only half arrived.

Category
Health Insights
Date
Reading time
11 min
Share

This post walks the fork that decides everything here: whether the disease sits in one place or many. It also covers why the diagnosis needs tissue rather than pictures, what the HHV-8 result changes, and why so many people arrive through a lymphoma work-up.

Why Are My Lymph Nodes Swollen If It Is Not Lymphoma? Castleman Disease

Why does a swollen node get investigated as lymphoma first?

Because that is the right order. A solitary enlarged node that keeps growing is a lymphoma question until tissue says otherwise, and Castleman disease is found at the end of that process rather than at the start. The international consensus guidelines for unicentric Castleman disease put it plainly: the disease is diagnosed after a lymph node biopsy, usually one taken for solitary swelling, often when lymphoma was suspected (Blood Advances, 2020). Those authors add that distinguishing lymphoma from unicentric Castleman disease can be challenging, because few diseases other than the two present with a single enlarged node carrying Castleman-like features under the microscope.

The multicentric form is confused for a different reason: its symptoms look like aggressive lymphoma from across the room. The Castleman Disease Collaborative Network states that the multicentric forms have symptoms and laboratory abnormalities similar to some aggressive lymphomas, and that this makes classification difficult. If night sweats are the reason you are reading this, our piece on the B symptoms that point to lymphoma covers how that cluster is normally chased down.

Ask Healz.

One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.

The lymphoma question also never fully closes. The unicentric guidelines record that Hodgkin and non-Hodgkin lymphoma can occur alongside unicentric Castleman disease, so the two are not strict alternatives, while adding that the risk of a lymphoma diagnosis alongside or after unicentric disease seems to be low, and the criteria for the idiopathic multicentric form require lymphoma to be excluded before that diagnosis is made at all (Blood, 2017).

Unicentric or multicentric: the fork everything else follows from

Everything you need to know follows from how many lymph node regions are involved.

Unicentric means a single enlarged node, or a single region of them, in one part of the body. It is the common form, making up roughly three in four cases according to Cleveland Clinic, and it is often found by accident. The consensus guidelines describe the diagnosis as frequently incidental, with the swelling often causing nothing at all and most cases showing no laboratory abnormalities (Blood Advances, 2020). When unicentric disease does cause trouble, the Castleman Disease Collaborative Network describes symptoms that come from enlarging nodes pressing on surrounding structures, rather than from whole-body inflammation. It is diagnosed at any age, 2 to 84 years in the published series, with a median of 34 and possibly a slight female predominance.

Multicentric means enlarged nodes in multiple regions, and it behaves like a different illness. The Castleman Disease Collaborative Network lists flu-like symptoms with fever and night sweats, loss of appetite, unintended weight loss, weakness, swelling and fluid collecting in the abdomen, an enlarged liver or spleen, kidney dysfunction, numbness in the hands and feet, and a rash of cherry haemangiomas, the small bright red skin growths. It is also diagnosed later in life, with the median age of onset reported in the fifth to seventh decades and an estimated United States incidence of about five cases per million person-years for the multicentric form, against roughly 21 to 25 per million for Castleman disease overall (Carbone and colleagues, Nature Reviews Disease Primers, 2021).

The practical consequence is blunt. In unicentric disease, complete surgical removal of the involved node is often curative and is the preferred first-line treatment where it is possible, and recurrence after a complete resection is uncommon (Blood Advances, 2020). In multicentric disease there is nothing to remove, because the problem is systemic, so the treatment is medical. That is why the work-up spends real effort on counting regions, not just on confirming the diagnosis.

Why is a biopsy of the node needed, and not just a scan?

Because a scan can tell you where the nodes are and how active they look, not what they are. A 2024 review in Cureus states that diagnostic imaging may not effectively distinguish Castleman disease from other lymphoproliferative disorders or cancers. The Castleman Disease Collaborative Network is equally direct: diagnosis requires biopsy of an enlarged lymph node and analysis by a pathologist, and cannot be made from symptoms alone.

Which biopsy matters too. For suspected unicentric disease, the consensus guidelines recommend a complete excisional lymph node biopsy rather than a fine-needle aspirate or a core biopsy (Blood Advances, 2020). The reason is architectural: the features that define Castleman disease, such as regressed germinal centres, plasma cell crowding and prominent vascularity, are patterns in the layout of the whole node, and a needle brings back cells without it. Our piece on what a sentinel node result actually changes shows the same principle in a different setting.

Imaging still has two jobs. The guidelines recommend CT of the neck, chest, abdomen and pelvis to establish how many lymph node stations are involved, which is the fork above. PET-CT can add information on how metabolically active the nodes are, with one caution worth repeating: high uptake values should raise the suspicion of lymphoma (Blood Advances, 2020). The scan sorts the geography. The tissue supplies the name.

What does HHV-8 change, and what does "idiopathic" mean?

Multicentric disease is split again by a single test on the biopsy. Some cases are driven by human herpesvirus 8, also known as the Kaposi sarcoma-associated herpesvirus. The rest have no identified cause, and those are called idiopathic multicentric Castleman disease, or iMCD.

That split is made on the node. The 2017 international consensus diagnostic criteria state that HHV-8 associated disease can be excluded by negative latency-associated nuclear antigen-1 staining, the LANA-1 stain, on a diagnostic lymph node, and that positive LANA-1 staining by immunohistochemistry is required to diagnose the HHV-8 associated form, which in turn excludes iMCD (Blood, 2017). The virus-driven form is more frequent in people living with HIV, though it also occurs in people who do not have HIV (per Carbone and colleagues, cited in the 2024 Cureus review).

Idiopathic means exactly what it says. The Castleman Disease Collaborative Network states that all cases of unicentric and idiopathic multicentric Castleman disease have an unknown cause. The mechanism is better understood than the trigger: interleukin-6 is the cytokine most associated with the systemic symptoms, which is why the treatments that work act on it.

The distinction changes two things. First, the diagnostic bar. iMCD is not diagnosed on histology alone. The 2017 criteria require both major criteria, meaning lymph node histopathology on the iMCD spectrum plus enlarged nodes in at least two stations, each one centimetre or more in short axis, together with at least two of eleven minor criteria, of which at least one must be a laboratory abnormality. The laboratory options are a raised CRP or ESR, anaemia, a low or high platelet count, low albumin, kidney dysfunction or protein in the urine, and polyclonal raised immunoglobulins; the clinical ones include constitutional symptoms, an enlarged liver or spleen and fluid accumulation. Uncontrolled infections including HHV-8 and HIV, autoimmune conditions such as lupus and adult-onset Still disease, and malignancies including Hodgkin and non-Hodgkin lymphoma, myeloma and POEMS syndrome must all be excluded as well. Two qualifiers come with that: an autoimmune diagnosis has to meet its own full clinical criteria, because autoantibodies alone do not exclude iMCD, and a malignancy counts as an exclusion only if it is diagnosed before or at the same time (Blood, 2017).

Second, the drug. Siltuximab, an antibody against interleukin-6, is the preferred first-line treatment for iMCD under the 2018 international consensus treatment guidelines, with tocilizumab as the substitute where siltuximab is unavailable, and corticosteroids added alongside it for initial disease control at a dose tailored to severity, high-dose in severely ill patients (Blood, 2018). Its United States approval in April 2014 is written for multicentric Castleman disease in patients who are HIV-negative and HHV-8-negative, and the manufacturer explains why: it was not studied in HIV-positive or HHV-8-positive patients because in preclinical work it did not bind the interleukin-6 those viruses produce. For the virus-driven form the evidence points instead to rituximab-based treatment, which a 2015 systematic review in HIV-1 infected and uninfected patients associated with better responses and survival than chemotherapy without it, while rating the evidence low quality and noting flares of Kaposi sarcoma. One stain decides which shelf the treatment comes from.

One subtype moves faster. TAFRO, standing for thrombocytopenia, anasarca, fever, renal failure and organomegaly, sits within idiopathic multicentric disease and tends to present with more severe features than conventional multicentric disease (per Masaki and colleagues, cited in the 2024 Cureus review).

How Healz works a case like this

This is a case with no single document in it that answers the question. The node report, the HHV-8 stain, the CRP and albumin, the platelet count, the CT that counted the stations: the diagnosis lives in the relationship between them, across weeks. Healz puts all of it in one chat instead of ten apps, and what makes that worth doing is what sits inside.

Frontier AI works your case, so the pathology report is read against your own blood results rather than in isolation. Healz is equipped with root-cause technology, which is why it does not stop at the first label: it cross-references your case against 1M+ rare cases and keeps asking what else fits a pattern of swollen nodes, fevers and abnormal bloods. Healz's memory holds every result you upload, dated, so a CRP from March and a platelet count from October read as one line rather than two screenshots. You can bring a board-certified doctor into the same chat for a second opinion.

Frequently asked questions

Is Castleman disease a cancer?

As of 2019 it is not considered a form of cancer, per the Castleman Disease Collaborative Network. Cleveland Clinic notes it still raises the chance of developing cancer, including lymphoma, and the Collaborative Network records an increased risk of blood cancers specifically in the idiopathic multicentric form.

Can Castleman disease be cured?

In unicentric disease, complete surgical removal of the involved node is often curative and is the preferred first-line treatment where surgery is possible, with recurrence afterwards uncommon (Blood Advances, 2020). Multicentric disease is not cured by surgery, because it is systemic, and is managed medically instead.

How is Castleman disease told apart from lymphoma?

By a lymph node biopsy read by a pathologist, not by a scan. The Castleman Disease Collaborative Network states the diagnosis requires a node biopsy and analysis, and a 2024 Cureus review notes imaging may not effectively separate Castleman disease from other lymphoproliferative disorders.

What does HHV-8 positive mean on my lymph node report?

In multicentric disease it means the illness is driven by human herpesvirus 8, and that the diagnosis is not iMCD. The 2017 consensus criteria require positive LANA-1 immunohistochemistry to diagnose the HHV-8 associated form, and that result excludes the idiopathic form. The two are treated differently.

What follow-up is needed after unicentric disease is removed?

The unicentric guidelines flag specific complications to watch for, including paraneoplastic pemphigus, bronchiolitis obliterans, AA amyloidosis and vascular tumours such as follicular dendritic cell sarcoma (Blood Advances, 2020). That is why review continues after an operation that was itself curative.

If the word Castleman has just appeared on your report, the thing to get answered next is not what it is called but how many regions are involved, because every other decision is waiting on that.

Written by Healz Team · Filed under Health Insights

Your health deserves more than guesswork

Get a real investigation, not a symptom list. Root causes found, history remembered, dots connected.

Not a medical provider. Healz.ai is an educational service. Always discuss every decision with your doctor. AI can make mistakes.

© 2026 HealzAI Inc1111B S Governors Ave #92123, Dover, DE 19904, USAMade with for better health